This meta-analysis of RCTs examines cardiovascular and renal outcomes in patients with and without CKD and includes results from the most recently published clinical trials with SGLT-2 inhibitors in patients with and without diabetes. The gene discussed is SLC5A2; the disease is chronic kidney disease.